Objective. Bone marrow oedema (BMO) and HLA-B27 are poor prognostic factors in axial SpA, and psoriasis is a poor prognostic factor in small-joint polyarthropathy. The aim of this study was to investigate the influence of HLA-B27, MRI BMO and psoriasis on long-term outcomes in early SpA-related knee joint oligoarthritis.
Introduction
The outcome of knee joint involvement in SpA-related oligoarthritis is highly variable, ranging from self-limiting to chronic arthritis [1, 2] . Until recently, the long-term outcome in patients with inflammatory back pain (IBP) was also poorly defined. However, in recent years, MRI has helped transform the understanding for the anatomical basis of SpA. Diffuse MRI determined that bone marrow oedema (BMO) is representative of osteitis in both the axial and appendicular skeleton [35] . The severity of BMO is linked to the presence of the HLA-B27 gene in the axial skeleton [6, 7] and peripheral skeleton at sites of major enthesis [8] . Persistence of BMO in the SI joints is also linked to HLA-B27 status [6] . Moreover, the severity of MRI SI joint BMO and HLA-B27 have also been shown to predict progression to radiographically defined modified New York criteria (mNYc) AS in the long-term follow-up of early IBP [9] .
Oligoarthritis, defined as an inflammatory arthritis affecting five or less joints [10] , with knee involvement is another frequent presentation in SpA, and tends to affect young people and can cause significant morbidity [11, 12] . However, unlike RA, the prognosis of early SpA-related knee disease is more variable. The data available is limited with variable outcomes [13, 14] , and is largely restricted to short-term studies [1013, 1518] with no long-term outcome studies available.
MRI is able to detect BMO in peripheral joints in SpA, and MRI BMO is a well-recognized feature in PsA [1921] . The severity of BMO is linked to HLA-B27, axial disease persistence and poor outcome [6, 8, 9, 22, 23] ; the presence of psoriasis is a poor prognostic feature in peripheral small-joint PsA [24, 25] and the presence of HLA-B27 is thought to be a poor prognostic factor in ReA [1, 2, 26] . The objective of this study was therefore to test the hypothesis that MRI BMO, HLA-B27 and the presence of cutaneous psoriasis are poor prognostic factors in SpA-related knee joint oligoarthritis.
Methods
This was a prospective correlational study of predictors of outcome over a 10-year follow-up period. Ethical approval was given by the Bradford National Health Service Research Ethics Committee. All patients gave their informed consent. Consecutive patients with seronegative oligoarthritis with knee involvement of suspected SpA origin were recruited from early arthritis clinics in West Yorkshire, UK. Inclusion criteria were oligoarthritis (five or fewer joints), including involvement of the knee, <4 years of symptoms, active clinical synovitis of the knee and negative RF. Patients were given standard treatments at the discretion of their treating rheumatologist.
Baseline assessment
The ESSG criteria for SpA [27] were assessed and MRI of the affected knee, RF and HLA-B27 were all performed. All patients had MRI T 1 -weighted spin-echo sagittal pulse sequences (T1SE) and T 2 -weighted turbo spin-echo coronal and sagittal pulse sequences with fat-suppression (T2 TSE/FS) using a Philips 1.5T Gyroscan ASC NT with a quadrature knee coil (Philips, Best, The Netherlands).
Follow-up outcome assessments
Follow-up included clinical, functional, serological and radiographic assessment. Clinical assessment included a 76/78 swollen/tender joint count, range of movement in the affected knee, re-assessment for ESSG criteria [27] and the Rheumatoid and Arthritis Outcome Score (RAOS) [28] . The RAOS is a validated, reliable and responsive outcome instrument in the form of an easy to complete patient-administered questionnaire designed to be used in inflammatory arthritis of the lower limb [28] . It assesses five components of outcome including pain, other symptoms (swelling, stiffness), function, as determined by activities of daily living (ADL) and sporting activities and quality of life (QoL). The questionnaire is scored between 0 and 100 (100 = excellent, 0 = bad).
CRP, anti-CCP (not available at the time of baseline assessment) and radiographs of the knee were also performed at follow-up. Patients were assessed for secondary OA with semi-flexed posterioranterior and lateral radiographs of the affected knee [2931] . The presence/absence and degree of radiographic OA was assessed using the Kellgren and Lawerence (KL) scoring system [32] .
Composite outcome score
The above measures offer isolated numerical values on a continuous or discrete scale of many different individual clinical, functional, serological and radiographic outcomes. To date, no valid reliable internationally recognized composite global outcome has been established in oligoarthritis. We therefore devised a global score based on the above measures to try and assess the overall outcome for this cohort of oligoarthritis patients as would be done in a clinical setting (Table 1 ).
MRI and radiographic scoring
All MRI scans and radiographs of the knee were scored by two experienced rheumatologists (D.McG./H.M.-O.), by consensus, blinded to clinical details and outcome. Scoring of the knee radiographs for OA was by the KL scoring method [32] (range Grades 0 = none to 4 = severe). To acknowledge the severity of OA in patients who had progressed to total knee replacement (TKR) and so as not to exclude them from statistical analysis, patients with TKR were given a score of 5. There are no validated and internationally recognized scoring systems for scoring MRI BMO of the knee in SpA. A qualitative scoring method has previously been published recording presence or absence of BMO at peri-entheseal locations by using a lesion counting scoring method [23] . However, to obtain quantitative scoring of knee joint BMO the whole-organ magnetic resonance imaging score (WORMS) of the knee in OA was used [33] . BMO was defined as poorly marginated areas of increased signal intensity in the normally fatty epiphyseal marrow on fat-suppressed T 2 -weighted fast-spin echo images. The BMO was graded from 0 to 3 on the extent of regional involvement in each of the well-described 14 articular surface regions ( Fig. 1 ) and one subspinous region, Grade 0 = none, Grade 1 = <25% of the region effected, 2 = 2550% and Grade 3 = >50%. Total scores for the whole-knee BMO including patellofemoral joint, ranging from 0 to 45 [33] .
In this study, however, the WORMS BMO scoring method was used to score the more diffuse BMO typically seen in SpA ( Fig. 2A and B) , and classical, localized OA BMO (kissing BMO) in peri-articular areas adjacent to sites with obvious articular cartilage loss at sites devoid of entheseal insertions was not scored.
Reliability of scoring
Intra-observer reliability was assessed, on 1420 sets of images at two separate time points, for both the BMO scoring by the WORMS method [33] , as described above, and scoring radiographic knee OA by the KL method [32] . The reliability for agreement between different grades of BMO in all 15 compartments scored was quadratic-weighted kappa (k w ) = 0.97. The range was from 0.90 (medial femoral anterior compartment) to 1.00 (medial patella compartment). The total BMO score intra-class correlation coefficient (ICC) was 0.99 (0.981.00). There was 100% agreement over the presence of effusion on MRI. For the KL scoring, agreement between different radiographic grades was k w = 0.99.
Sample size and statistical analysis
Power analysis was based on a minimum of 510 participants per predictor variable for logistic regression analysis to be performed [34] . Three predictors of outcome-knee MRI BMO, presence of PsA and HLA-B27 status-were assessed, therefore a minimum of 30 patients were recruited to the study. Logistic regression analysis was performed on the predictor variables, using the abovedescribed clinical, radiographic and functional assessments as outcome measures. MannWhitney U-test, 2 test and r correlation statistics were also performed. All statistical analyses were carried out in SPSS version 15.0.1.1.
Results

Baseline demographics
Forty-four patients were recruited [mean age 32 years (range 1559 years), 70% male] with a mean disease duration at baseline of 9.75 months (148 months). The diagnoses at baseline according to ESSG criteria [27] were 17 (39%) PsA, 12 (27%) ReA, 9 (20%) undifferentiated oligoarthritis, 4 (9%) AS and 2 (5%) IBD-related SpA ( Table 2 ). All patients were RF negative and 42% [18/43 (one result lost in lab)] were HLA-B27 positive.
Baseline MRI imaging
The mean total BMO score for the whole-knee MRI was 2.86 (range 029). Twenty-five (57%) patients had no (Fig. 3) and the most mildly affected area was the central position of the medial tibial condyle (total BMO = 4). Classical localized mild OA BMO in peri-articular areas was present in only two cases.
Outcomes
Clinical Twenty-six (59%) patients (mean age 43 years, 65% male) returned for follow-up after a mean of 10 years (range 8.412.6 years). The diagnoses at follow-up were 10 (38%) PsA, 7 (27%) ReA, 4 (15%) undifferentiated oligoarthritis, 3 (12%) AS and 2 (8%) IBD-related SpA. All patients were RF negative and 36% (9/25) were HLA-B27 positive. Anti-CCP measured at follow-up was negative in all patients with the exception of one, who was RF negative with psoriasis and diagnosed as having psoriatic oligoarthritis. The mean swollen joint count was 1.7 (range 124) and the mean tender joint count was 4 (range 072). Ten (38%) patients had persistent clinical synovitis at a mean of 10 years follow-up. One PsA patient had developed polyarticular small-joint disease but was RF and anti-CCP negative and was still deemed to be PsA. Eighty-one per cent (21/26) of patients had a full range of movement in the affected knee. One (3.8%) PsA patient had had a total knee replacement. The mean CRP at follow-up was 11.4 mg/l (range <5.0 to 125). Three of the four highest CRP values were from PsA patients, but overall there was no significant difference in median CRP values between PsA and other diagnoses (P = 0.461). sports activities, 62.0% (range 0100); and QoL, 65% (range 6.3100). This indicates that the group as a whole complained of moderate symptoms, pain and reduction in ADL resulting in a more marked reduction in QoL and sporting activities.
Radiographic
In the group as a whole, radiographic outcome was in general good, with a mean KL score of 1.1 (range 05), indicating only doubtful radiographic OA, defined as 'doubtful narrowing of joint space and possible osteophytic lipping' [34] . Overall 31% (8/26) had definite radiographic OA (KL grade 52) at 10 years follow-up. PsA patients as a group had the worst KL scores with a median of 2 equating to definite osteophyte formation and possible narrowing of the joint space [32] compared with other diagnoses; however, this was not significantly different (P = 0.144).
Composite score
With the use of the described composite score only 3/26 (11.5%) patients had an excellent or a good outcome and 18/26 (69%) had a poor or very poor outcome.
Predictors of knee MRI BMO
HLA-B27
HLA 
Presence of BMO
Presence of any grade of BMO was not significantly associated with KL score (P = 0.798), RAOS symptoms (P = 0.588), pain (P = 0.549), ADL (P = 0.511), sports activity (P = 0.588) or QoL (P = 0.288).
HLA-B27
There was no significant association between HLA-B27 and worse KL grade [HLA-B27 negative n = 15, median (IQR) = 1 (02); positive n = 9, median (IQR) = 0 (01); MannWhitney U-test = 55.0, P = 0.482], or between HLA-B27 and worse RAOS score.
Diagnosis predicting outcome
The ReA group had the best outcome, with 5/7 (71%) of ReA having an excellent, good or moderate outcome, and 5/8 (62.5%) of all patients with a good or moderate response being ReA. Conversely, PsA and AS patients had the worst knee-specific outcome with 9/10 (90%) of PsA and 3/3 (100%) of AS patients having a poor or very poor outcome. The global outcome in PsA was significantly worse (continuity-corrected 2 P = 0.036) than ReA, with only 2/7 (28.5%) of ReA having a poor/very poor outcome. PsA patients also had significantly worse symptoms (pain: P = 0.001, other symptoms: P = 0.004), function (ADL: P = 0.001, sport and recreation: P = 0.001) and QoL (P = 0.004) than other diagnoses (Table 3) .
Discussion
This is the first long-term study investigating outcome and predictors of outcome in oligoarthritis related to SpA using baseline MRI in combination with genetic and clinical parameters. We tested the concept that MRI BMO in the knee could be used to prognosticate in a manner similar to MRI in axial disease in SpA [69, 35] . We found no association between HLA-B27 or psoriasis and presence or severity of BMO in the knee of oligoarthritis patients, and also no association between BMO and long-term clinical and radiographic outcome. A clinical parameter, namely the presence of psoriasis, was the best long-term predictor of early SpA-related knee disease. It remains to be defined why MRI BMO and/or HLA-B27 have no obvious parallels between knee and axial disease.
We have shown that over a 10-year period, in the cohort as a whole, radiographic secondary OA is present in 31% of the affected knees, 38% have persistent clinical synovitis and that global 10-year outcome was poor or very poor in 69% of cases despite the use of standard treatments with either IA steroid and/or DMARDs. In particular, long-term QoL and ability to perform sporting activities were affected, the significance of which should not be underestimated in this young cohort. In terms of subclasses of SpA there was a clear divide, with PsA patients having a significantly worse outcome and the majority of ReA patients having a good outcome. PsA patients had a worse radiographic OA score, a higher CRP and 90% had a poor or very poor global outcome, which was significantly worse than ReA. All self-reported elements of outcome were significantly worse in PsA patients compared with the other diagnoses.
Before this study, studies investigating predictors of outcome in oligoarthritis were limited to early intervention and short-term outcome [10, 18] . The two published studies have shown that early intervention with IA steroid into active joints (open-label study) [10] or early IA steroid and SSZ [in a randomized controlled trial (RCT)] [18] results in better short-term responses than no/conventional treatment; however, >50% of patients still had active synovitis at 52 weeks [10] in the open-label study and there was still significant disease with function and work disability at 12 months in the RCT [18] . There were no baseline predictors of persistent disease identified in either study.
Our study has some limitations. Eighteen patients failed to return for follow-up, which is a recognized problem of long-term outcome studies, resulting in relatively small numbers with complete data sets in the cohort. All AS patients had a poor or very poor long-term outcome, but as there were only three AS patients at follow-up, we felt it unwise to conclude too much from this result. The choice of assessment of secondary OA of the knee at follow-up was radiographs, which are still the gold standard. It is recognized that MRI and arthroscopy are more sensitive to early OA changes [36, 37] ; however, for the purpose of the study these were not practical options. The KL method [32] of radiographic assessment for OA is also an old scoring system. Criticisms of it are that it is relatively insensitive to change; however, radiographic change was not assessed in this study, just radiographic OA severity at follow-up. For the purpose of screening subjects for a radiographic diagnosis and severity of OA, the KL scoring system is still regarded as an adequate tool [38] . Furthermore, we recognize that the composite clinical global outcome tool used is simple and has not previously been tested or validated; however, it gives a practical assessment option comprising clinical, serological, radiographic and functional outcomes similar to what would be used in everyday clinical practice and is, in our option, a better global outcome than any of the individual outcome measures used in isolation. Finally, the study did not quantify synovitis in the knee on MRI, the magnitude of which has been previously related to prognosis in RA [39] .
In conclusion, the study confirms, at best, moderate to poor 10-year outcome of SpA-associated oligoarthritis despite standard clinical treatment. The study has not identified biological predictors of long-term outcome in oligoarthritis, but has identified PsA-associated oligoarthritis as having a significantly worse prognosis than other subtypes of SpA-related oligoarthritis.
Rheumatology key messages
. Poor outcome of oligoarthritis involving the knee at 10 years is common. . Radiographic OA occurs in one-third of oligoarthritis patients at 10 years. . The presence of psoriasis is a bad prognostic factor in oligoarthritis involving the knee.
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